Edition:
India

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

6.37USD
9:51pm IST
Change (% chg)

$0.11 (+1.76%)
Prev Close
$6.26
Open
$6.33
Day's High
$6.40
Day's Low
$6.31
Volume
154,000
Avg. Vol
508,256
52-wk High
$8.29
52-wk Low
$3.50

Latest Key Developments (Source: Significant Developments)

TherapeuticsMD Announces Resubmission Of New Drug Application For TX-004HR
Thursday, 30 Nov 2017 

Nov 29 (Reuters) - TherapeuticsMD Inc ::THERAPEUTICSMD ANNOUNCES RESUBMISSION OF NEW DRUG APPLICATION FOR TX-004HR.THERAPEUTICSMD INC - COMPANY EXPECTS TO LEARN OF ACCEPTANCE OF NDA RESUBMISSION WITHIN 30 CALENDAR DAYS.  Full Article

TherapeuticsMD reports Q3 loss per share of $0.07
Monday, 6 Nov 2017 

Nov 6 (Reuters) - Therapeuticsmd Inc ::TherapeuticsMD announces third quarter 2017 financial results.Q3 loss per share $0.07.Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S.Q3 revenue $4.4 million versus i/b/e/s view $5.2 million.  Full Article

TherapeuticsMD announces plan to resubmit the new drug application for TX-004HR
Monday, 6 Nov 2017 

Nov 6 (Reuters) - TherapeuticsMD Inc :TherapeuticsMD Inc announces plan to resubmit the new drug application for TX-004HR.TherapeuticsMD Inc - Division of bone,reproductive & urologic products, US FDA agreed to NDA resubmission for TX-004HR without additional pre-approval study​.TherapeuticsMD Inc - ‍on Nov 3 co participated in an in-person meeting with division of bone, reproductive, and urologic products of US FDA​.TherapeuticsMD Inc - ‍co will commit to conduct a post-approval observational study​.  Full Article

Therapeuticsmd reports Q2 loss per share $0.11
Friday, 5 Aug 2016 

Therapeuticsmd Inc : Therapeuticsmd announces second quarter 2016 financial results . Q2 loss per share $0.11 . Q2 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S .Topline phase 3 data for tx-001hr replenish trial on track for q4 of 2016.  Full Article

TherapeuticsMD, Inc announces pricing of common stock offering
Thursday, 7 Jan 2016 

TherapeuticsMD, Inc:Announces pricing of $125 million common stock offering.Says public offering priced at $8.25 per share.  Full Article

TherapeuticsMD Announces $125 Million Offering of Common Stock
Wednesday, 6 Jan 2016 

TherapeuticsMD, Inc:Says launch of an underwritten public offering of $125 million of shares of its common stock.expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock.All of the shares in the offering are to be sold by TherapeuticsMD.The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.Goldman, Sachs & Co. and Cowen and Company are acting as joint bookrunning managers for the offering.Stifel is acting as joint lead manager for the offering and Guggenheim Securities is acting as co-manager for the offering.intends to use a majority of the proceeds of the offering to fund commercialization activities for TX-004HR, its applicator-free vaginal estradiol softgel drug candidate, for other research, clinical trials, clinical formulation and development and for working capital and general corporate purposes.  Full Article

BRIEF-TherapeuticsMD reports Q3 loss per share of $0.07

* TherapeuticsMD announces third quarter 2017 financial results